Log in to search using one of your social media accounts:

 

ZYTIGA ® (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer

Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news

Related Links:

The thumbnail take on finasteride has been that it prevents prostate cancer but increases the risk for high-grade disease. A new study debunks the latter idea.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
In a novel study, the three leading prostate cancer genomics tests, which are used to help stratify favorable-risk cancers and to aid decision-making about active surveillance, were compared.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
In this study, chitosan was used to coat the adsorbent for preventing the leakage of Zn2+ loaded. Meanwhile, freeze-drying method was used to enhance adsorption capacity of Zn2+-loaded cellulose beads for testosterone. The results indicate that after the adsorbent was coated by 0.02% chitosan solution, the highest adsorption percentage reached 48%, during adsorption, the Zn2+ concentration in plasma did not increase; the adsorption capacity of the adsorbent can be significantly enhanced by freeze-drying. The results may be caused by porosity of the adsorbent enlarged via freeze-drying and improved stability by coating with...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
Conclusions: When AA was administered without goserilin, only 78% achieved castration levels. AA combined with SRT and goserilin did not increase pelvic toxicity, but lead to an unsuspected high frequency of grade 3 liver toxicity. The phase II recommended dose of AA combined to goserelin and SRT is 750 mg. PMID: 29774129 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
(SWOG) Twenty five years after it opened for enrollment, the landmark Prostate Cancer Prevention Trial has delivered a final verdict. Finasteride, a common hormone-blocking drug, reduces mens' risk of getting prostate cancer without increasing their risk of dying from the disease.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
(MedPage Today) -- Discordance between tests, with NCCN risk criteria
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
CONCLUSIONS: PER3 can induce sensitivity of paclitaxel-resistant cell lines to paclitaxel by inhibiting the expression of Notch1. PMID: 29771413 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Publication date: Available online 18 May 2018 Source:European Urology Author(s): Jennifer A. Sinnott, Katherine Brumberg, Kathryn M. Wilson, Ericka M. Ebot, Edward L. Giovannucci, Lorelei A. Mucci, Jennifer R. Rider In a prospective study of 31 925 men with 18 yr of follow-up, higher ejaculation frequency (EF) throughout adulthood was associated with lower rates of prostate cancer. To further explore this association, we evaluated whole transcriptome gene expression in the prostate tissue from study participants who developed prostate cancer between 1992 and 2004 (n =157 tumor tissue, n =85 adjacent normal). We tested fo...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Chen Hao Lo, Conor C. Lynch
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Pharmaceuticals | Prednisone | Prostate Cancer